These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1296 related items for PubMed ID: 26707273

  • 1. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
    Mauskopf J, Fay M, Iyer R, Sarda S, Livingston T.
    J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
    [Abstract] [Full Text] [Related]

  • 2. The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada.
    Su W, Kansal A, Vicente C, Deniz B, Sarda S.
    J Med Econ; 2016 Jul; 19(7):718-27. PubMed ID: 27080475
    [Abstract] [Full Text] [Related]

  • 3. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
    Maruszczak MJ, Montgomery SM, Griffiths MJ, Bergvall N, Adlard N.
    J Med Econ; 2015 Jul; 18(11):874-85. PubMed ID: 26055952
    [Abstract] [Full Text] [Related]

  • 4. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
    Soini E, Joutseno J, Sumelahti ML.
    Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
    [Abstract] [Full Text] [Related]

  • 5. Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective.
    Chevalier J, Chamoux C, Hammès F, Chicoye A.
    PLoS One; 2016 Mar; 11(3):e0150703. PubMed ID: 26987055
    [Abstract] [Full Text] [Related]

  • 6. The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada.
    Dorman E, Kansal AR, Sarda S.
    J Med Econ; 2015 Mar; 18(12):1085-91. PubMed ID: 26390149
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
    Hernandez L, Guo S, Kinter E, Fay M.
    J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
    [Abstract] [Full Text] [Related]

  • 9. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
    Fox RJ, Chan A, Zhang A, Xiao J, Levison D, Lewin JB, Edwards MR, Marantz JL.
    Curr Med Res Opin; 2017 Feb; 33(2):175-183. PubMed ID: 27733070
    [Abstract] [Full Text] [Related]

  • 10. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.
    Giovannoni G, Gold R, Fox RJ, Kappos L, Kita M, Yang M, Sarda SP, Zhang R, Viglietta V, Havrdova E.
    Clin Ther; 2015 Nov 01; 37(11):2543-51. PubMed ID: 26526385
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
    Fernández Ó, Giovannoni G, Fox RJ, Gold R, Phillips JT, Potts J, Okwuokenye M, Marantz JL.
    Clin Ther; 2017 Aug 01; 39(8):1671-1679. PubMed ID: 28751099
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia.
    Alsaqa'aby MF, Vaidya V, Khreis N, Khairallah TA, Al-Jedai AH.
    Ann Saudi Med; 2017 Aug 01; 37(6):433-443. PubMed ID: 29229891
    [Abstract] [Full Text] [Related]

  • 13. Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States.
    Chirikov V, Ma I, Joshi N, Patel D, Smith A, Giambrone C, Cornelio N, Hashemi L.
    Value Health; 2019 Feb 01; 22(2):168-176. PubMed ID: 30711061
    [Abstract] [Full Text] [Related]

  • 14. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
    Braune S, Grimm S, van Hövell P, Freudensprung U, Pellegrini F, Hyde R, Bergmann A, NTD Study Group.
    J Neurol; 2018 Dec 01; 265(12):2980-2992. PubMed ID: 30327931
    [Abstract] [Full Text] [Related]

  • 15. When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing-remitting multiple sclerosis.
    Noon KM, Montgomery SM, Adlard NE, Kroes MA.
    J Med Econ; 2018 Oct 01; 21(10):983-992. PubMed ID: 29923439
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
    Lee S, Baxter DC, Limone B, Roberts MS, Coleman CI.
    J Med Econ; 2012 Oct 01; 15(6):1088-96. PubMed ID: 22583065
    [Abstract] [Full Text] [Related]

  • 17. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
    English C, Aloi JJ.
    Clin Ther; 2015 Apr 01; 37(4):691-715. PubMed ID: 25846320
    [Abstract] [Full Text] [Related]

  • 18. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies.
    Kita M, Fox RJ, Gold R, Giovannoni G, Phillips JT, Sarda SP, Kong J, Viglietta V, Sheikh SI, Okwuokenye M, Kappos L.
    Clin Ther; 2014 Dec 01; 36(12):1958-1971. PubMed ID: 25315404
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study.
    Kresa-Reahl K, Repovic P, Robertson D, Okwuokenye M, Meltzer L, Mendoza JP.
    Clin Ther; 2018 Dec 01; 40(12):2077-2087. PubMed ID: 30470580
    [Abstract] [Full Text] [Related]

  • 20. Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.
    Walter E, Berger T, Bajer-Kornek B, Deisenhammer F.
    J Med Econ; 2019 Mar 01; 22(3):226-237. PubMed ID: 30522373
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 65.